Quince Therapeutics announces fast track designation for EryDex System

Quince Therapeutics announced that the FDA has granted Fast Track designation for its EryDex System for the treatment of patients with Ataxia-Telangiectasia, or A-T. EryDex is comprised of dexamethasone sodium phosphate, or DSP, encapsulated in a patient’s own red blood cells utilizing Quince’s proprietary Autologous Intracellular Drug Encapsulation, or AIDE, technology platform. DSP is a corticosteroid well known for its anti-inflammatory properties as well as its dose-limiting toxicity due to adrenal suppression. EryDex is designed to provide the efficacy of corticosteroids and to reduce or eliminate the significant adverse effects that accompany chronic corticosteroid treatment.